Vernal keratoconjunctivitis (VKC) is a severe perennial form of allergic conjunctivitis involving the cornea and conjunctiva. The condition is found predominantly in children or young adults and commonly in atopic individuals, who may also suffer from eczema, asthma, or hayfever. The disease generally affects the upper tarsal conjunctiva, which shows a papillary hypertrophy which has a 'cobblestone' appearance in severe cases. The main symptoms are severe itching and the production of a tenacious stringy mucous discharge. The limbal conjunctiva may also be affected, either as a localised oedema and hyperaemia or as fleshy isolated vegetations. It is considered to be an atopic disease' and has been classified as a type I allergic disease of the outer eye.2
Although VKC responds well to the instillation of corticosteroid drops, not all cases achieve complete control, and long-term use of steroids in the eye is known to produce glaucoma.3 The high incidence rate of the disease in Egypt along with incomplete amelioration with the use of antihistamines, vasoconstrictors, and steroids made the study of other possible therapeutic agents very desirable.
Such an alternative agent was sodium cromoglycate (SCG), which, in addition to its effectiveness in the treatment of asthma,4 rhinitis,fi 7 proctitis,8 and ulcerative colitis,9 was reported'01l to be effective when applied topically to the conjunctiva in 
Materials and methods
A total of 89 patients were selected in whom the disease had equal intensity in both eyes and the duration had varied up to 15 years. All these patients were in continual contact with the clinician through the year prior to the study and also during the whole study period. During the 12-month period only 6 patients dropped out of the trial.
The patients were divided into the following Fifty-nine patients with acute vernal disease were entered in this group. The incidence of atopy and other allergic conditions was very low (Table 1) . The first patient entered in the trial was assessed in a different manner and his results have been excluded from the analysis. The total sample size for this group is therefore 58.
Comparison of the subjective and objective scores recorded before the start of the trial and after subsequent visits showed a statistically signifi- Comparison of the subjective and objective scores recorded before the start of the trial and after subsequent visits for the right and left eyes respectively showed a statistically significant difference in favour of SCG eyedrops. In the case of the subjective scores after 8 months' treatment a significant difference (P<0 02) was seen in 6 out of 7 variables, while in the objective scores all but 2 of the variables showed a significant difference in favour of SCG eyedrops (P<0-01).
Clinical assessments made after I and 8 months' treatment of overall efficacy, patient's opinion, clinical response, and side effects showed that a high percentage of patients found the SCG eyedrops superior to Antistin-Privine for all the variables (Table 3) . Only 1 report of stinging was reported for each treatment after 8 months.
Clinical trial with 20 sodium cromoglycate (Opticrom) in vernal keratoconjunctivitis Table 1) . The subjective measurements recorded after 10 days and 1 and 8 months did not reveal a significant difference between the 2 treatments for any of the variables except stinging, where SCG eyedrops were found to sting significantly more than Decadron.
Comparison of the objective scores recorded after subsequent visits for the right and left eyes respectively showed that after 8 months' treatment both treatments performed equally for all the variables except 3, the exceptions being pigmentation, corneal vascularisation and ocular tension, which showed significant differences in favour of SCG eyedrops. In the case of ocular tension there was an increase in the eye given Decadron and a decrease in the eye given SCG.
Six right eyes out of 15 receiving Decadron showed an increase of ocular tension, with an average of +0 9 mmHg (Schi0tz) after 1 month's treatment, and SCG-treated eyes showed no difference (Table 4) .
Eight Decadron treated eyes showed an increase in ocular tension by an average of +1 -2 mmHg after 8 months' treatment, and SCG treated eyes showed a decrease of an average of 0 2 mmHg (Table 4) . After 1 year no further change of the tension was recorded.
The clinical assessments made after 1 and 8 months' treatment revealed an equivalent response from both treatments (Table 5) .
In all these groups the results after 12 months' treatment were similar to those presented after 8 months.
Discussion
Fifty-eight patients were administered 2% SCG eyedrops as sole therapy, and after 8 months' treatment the efficacy was rated as high in 42 patients, moderate/mild in 13, and nil in 3. Such a response indicates that SCG may block an important element of type I hypersensitivity which is thought to exist in VKC.10 In some patients additional treatment with topical steroid was found necessary at the start of treatment or during acute exacerbations. Thus, 8 patients out of 88 received steroid therapy for 1 week at the start of the trial in the severe forms of the disease. However, since the overall steroid requirement was removed in many patients and considerably reduced in others, this has helped greatly to remove the unwanted side effects of topical steroid therapy in VKC, such as increased Table 4 Differences between changes in ocular tension after I and 8 months 
